当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
IXINITY, Coagulation Factor IX (Recombinant)
申请企业
Aptevo BioTherapeutics LLC
药品名称
IXINITY, Coagulation Factor IX (Recombinant)
承诺描述
Deferred pediatric study IB1001-02B under PREA for the treatment of hemophilia B in pediatric patients ages 0-12. Final Protocol Submission: Received on November 6, 2015